NASDAQ:OLMA Olema Pharmaceuticals (OLMA) Stock Price, News & Analysis → $21,000 in profits in six weeks? (From InvestorPlace) (Ad) Free OLMA Stock Alerts $10.85 -0.39 (-3.47%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$10.59▼$11.0250-Day Range$9.83▼$14.8052-Week Range$5.02▼$17.79Volume611,232 shsAverage Volume773,949 shsMarket Capitalization$606.84 millionP/E RatioN/ADividend YieldN/APrice Target$21.43 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Olema Pharmaceuticals alerts: Email Address Olema Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside97.5% Upside$21.43 Price TargetShort InterestBearish16.04% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.28Based on 11 Articles This WeekInsider TradingSelling Shares$726,900 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.34) to ($2.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.53 out of 5 starsMedical Sector667th out of 905 stocksPharmaceutical Preparations Industry309th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingOlema Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOlema Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Olema Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted16.04% of the outstanding shares of Olema Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverOlema Pharmaceuticals has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.Change versus previous monthShort interest in Olema Pharmaceuticals has recently increased by 10.74%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOlema Pharmaceuticals does not currently pay a dividend.Dividend GrowthOlema Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OLMA. Previous Next 1.8 News and Social Media Coverage News SentimentOlema Pharmaceuticals has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Olema Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for OLMA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Olema Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Olema Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $726,900.00 in company stock.Percentage Held by Insiders23.50% of the stock of Olema Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.78% of the stock of Olema Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Olema Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Olema Pharmaceuticals are expected to decrease in the coming year, from ($2.34) to ($2.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Olema Pharmaceuticals is -5.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Olema Pharmaceuticals is -5.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOlema Pharmaceuticals has a P/B Ratio of 2.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Olema Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThe new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.Pay close attention to this important video About Olema Pharmaceuticals Stock (NASDAQ:OLMA)Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.Read More OLMA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OLMA Stock News HeadlinesMay 8, 2024 | insidertrades.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon Sells 5,000 SharesMay 3, 2024 | insidertrades.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $142,650.00 in StockMay 9, 2024 | InvestorPlace (Ad)The new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.May 8, 2024 | investorplace.comOLMA Stock Earnings: Olema Pharmaceuticals Misses EPS for Q1 2024May 8, 2024 | globenewswire.comOlema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 8, 2024 | globenewswire.comOlema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual CongressMay 4, 2024 | americanbankingnews.comCyrus Harmon Sells 15,000 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) StockMay 2, 2024 | globenewswire.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 9, 2024 | InvestorPlace (Ad)The new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.May 1, 2024 | globenewswire.comOlema Oncology to Participate in Upcoming Investor Conferences in MayApril 21, 2024 | finance.yahoo.comOlema Pharmaceuticals, Inc. (OLMA)April 12, 2024 | markets.businessinsider.comBuy Rating on Olema Pharmaceuticals Amidst Promising Oncology Developments and Competitive EdgeApril 10, 2024 | bizjournals.comHow Olema Oncology moved from layoffs to pivotal cancer drug studiesApril 8, 2024 | globenewswire.comOlema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual ConferenceApril 2, 2024 | globenewswire.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 28, 2024 | seekingalpha.comPalazestrant's Journey: Olema Pharmaceuticals' Long Oncology PathMarch 16, 2024 | finance.yahoo.comOLMA Jul 2024 12.500 callMarch 16, 2024 | finance.yahoo.comOLMA Apr 2024 22.500 callMarch 15, 2024 | ca.finance.yahoo.comOLMA Oct 2024 25.000 callMarch 15, 2024 | ca.finance.yahoo.comOLMA Oct 2024 10.000 putMarch 13, 2024 | msn.com3 Best Stocks to Buy Now, 3/13/2024, According to Top AnalystsMarch 12, 2024 | markets.businessinsider.comBuy Rating Justified for Olema Pharmaceuticals Amidst Promising Trial Results and Significant Market OpportunityMarch 12, 2024 | markets.businessinsider.comBuy Rating for Olema Pharmaceuticals Based on Promising Palazestrant and Ribociclib Combination in ER+ Breast Cancer TreatmentMarch 12, 2024 | markets.businessinsider.comStrong Clinical Progress and Market Potential: Buy Rating for Olema Pharmaceuticals’ PalazestrantMarch 11, 2024 | globenewswire.comOlema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdateMarch 6, 2024 | markets.businessinsider.comBuy Rating for Olema Pharmaceuticals’ Palazestrant Based on Dual Action Efficacy and Strategic Compatibility in ER+ Breast Cancer TreatmentMarch 6, 2024 | finance.yahoo.comOlema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 InhibitorsSee More Headlines Receive OLMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Olema Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/11/2024Today5/08/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OLMA CUSIPN/A CIK1750284 Webwww.olema.com Phone650-243-5555FaxN/AEmployees74Year FoundedN/APrice Target and Rating Average Stock Price Target$21.43 High Stock Price Target$28.00 Low Stock Price Target$18.00 Potential Upside/Downside+100.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-96,650,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-44.67% Return on Assets-40.99% Debt Debt-to-Equity RatioN/A Current Ratio12.33 Quick Ratio12.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.61 per share Price / Book2.31Miscellaneous Outstanding Shares55,930,000Free Float42,790,000Market Cap$596.77 million OptionableOptionable Beta2.10 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Sean P. Bohen M.D. (Age 57)Ph.D., President, CEO & Director Comp: $1MMr. Shane William Charles Kovacs M.B.A. (Age 50)Chief Operating & Financial Officer Comp: $726.17kDr. Naseem Zojwalla M.D. (Age 51)Chief Medical Officer Comp: $775.48kMr. Geoffrey MogilnerVice President of Investor Relations & CommunicationsMs. Julie DexterSenior VP & Head of PeopleDr. David C. Myles Ph.D. (Age 61)Chief Discovery & Non-Clinical Development Officer Comp: $200kMs. Demiana Faltaos Ph.D.Pharm.D., VP & Head of Clinical PharmacologyMr. John B. Moriarty Jr. (Age 56)J.D., Corporate Secretary Comp: $434.32kMs. Sasha Austin CPAVP of Finance & ControllerMore ExecutivesKey CompetitorsGH ResearchNASDAQ:GHRSStoke TherapeuticsNASDAQ:STOKCalliditas Therapeutics AB (publ)NASDAQ:CALTZymeworksNYSE:ZYMEPharming GroupNASDAQ:PHARView All CompetitorsInsiders & InstitutionsEntropy Technologies LPBought 14,246 shares on 5/8/2024Ownership: 0.025%Swiss National BankBought 5,700 shares on 5/7/2024Ownership: 0.126%ClariVest Asset Management LLCSold 6,200 shares on 5/7/2024Ownership: 0.110%Susquehanna Portfolio Strategies LLCSold 1,800 shares on 5/7/2024Ownership: 0.062%Susquehanna Fundamental Investments LLCBought 15,565 shares on 5/7/2024Ownership: 0.028%View All Insider TransactionsView All Institutional Transactions OLMA Stock Analysis - Frequently Asked Questions Should I buy or sell Olema Pharmaceuticals stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Olema Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OLMA shares. View OLMA analyst ratings or view top-rated stocks. What is Olema Pharmaceuticals' stock price target for 2024? 7 brokerages have issued twelve-month price targets for Olema Pharmaceuticals' shares. Their OLMA share price targets range from $18.00 to $28.00. On average, they anticipate the company's stock price to reach $21.43 in the next twelve months. This suggests a possible upside of 97.5% from the stock's current price. View analysts price targets for OLMA or view top-rated stocks among Wall Street analysts. How have OLMA shares performed in 2024? Olema Pharmaceuticals' stock was trading at $14.03 at the beginning of 2024. Since then, OLMA stock has decreased by 22.7% and is now trading at $10.85. View the best growth stocks for 2024 here. Are investors shorting Olema Pharmaceuticals? Olema Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 8,100,000 shares, an increase of 60.1% from the March 15th total of 5,060,000 shares. Based on an average daily volume of 822,200 shares, the days-to-cover ratio is presently 9.9 days. View Olema Pharmaceuticals' Short Interest. When is Olema Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our OLMA earnings forecast. How were Olema Pharmaceuticals' earnings last quarter? Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) released its quarterly earnings data on Monday, March, 11th. The company reported ($0.49) earnings per share for the quarter, hitting the consensus estimate of ($0.49). When did Olema Pharmaceuticals IPO? Olema Pharmaceuticals (OLMA) raised $170 million in an initial public offering on Thursday, November 19th 2020. The company issued 10,000,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Cowen and Canaccord Genuity acted as the underwriters for the IPO. Who are Olema Pharmaceuticals' major shareholders? Olema Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Swiss National Bank (0.13%), ClariVest Asset Management LLC (0.11%), Susquehanna Portfolio Strategies LLC (0.06%), Susquehanna Fundamental Investments LLC (0.03%), Entropy Technologies LP (0.03%) and China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include Biocapital Advisors L Paradigm, Bvf Partners L P/Il, Cyrus Harmon, David C Myles, G Walmsley Graham, Kinney Horn, Naseem Zojwalla and Sean Bohen. View institutional ownership trends. How do I buy shares of Olema Pharmaceuticals? Shares of OLMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OLMA) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.